|
Ronn (K2)
|
2020
|
375 μg
|
800 mg
|
K2
|
3 year
|
Denmark
|
NR
|
67.4
|
62/57
|
Femoral neck, hip
|
NR
|
NR
|
− 10/− 8
|
NR
|
|
Zhang et al. (K2)
|
2020
|
90 µg
|
500 mg
|
K2
|
1 year
|
China
|
23.5
|
65.9
|
81/74
|
Lumbar spine, femoral neck, hip
|
2/− 4
|
NR
|
− 3/− 3
|
NR
|
|
Kanellakis et al.(K2)
|
2012
|
100 μg
|
800 mg
|
K2
|
1 year
|
Greece
|
29.43
|
62
|
24/26
|
Lumbar spine, UcOC, total body
|
6/− 32
|
13/24
|
NR
|
− 23.6/28.7
|
|
Kanellakis et al. (K1)
|
2012
|
100 μg
|
800 mg
|
K1
|
1 year
|
Greece
|
30.06
|
62
|
26/26
|
Lumbar spine, UcOC, total body
|
16/− 32
|
13/24
|
NR
|
− 13.6/28.7
|
|
Je et al. (K2)
|
2011
|
45 mg
|
1200 mg
|
K2
|
4 year
|
Korea
|
NR
|
67.3
|
18/27
|
Lumbar spine, UcOC, femoral neck
|
10/− 8
|
NR
|
10/10
|
− 72.2/− 25
|
|
Moschonis et al.(K2)
|
2011
|
100 μg
|
800 mg
|
K2
|
1 year
|
Greece
|
29.65
|
62
|
24/39
|
Lumbar spine, UcOC, total body
|
6/− 8
|
13/− 1
|
NR
|
− 23.6/12.8
|
|
Moschonis et al. (K1)
|
2011
|
100 μg
|
800 mg
|
K1
|
1 year
|
Greece
|
30
|
62
|
26/39
|
Lumbar spine, UcOC, total body
|
16/− 8
|
13/− 1
|
NR
|
− 13.6/12.8
|
|
Shiraki (K2)
|
2009
|
45 mg
|
133 mg
|
K2
|
0.5 year
|
Japan
|
NR
|
68
|
55/49
|
UcOC
|
NR
|
NR
|
NR
|
− 57.1/− 25
|
|
Booth et al. (MK1)
|
2008
|
500 μg
|
600 mg
|
K1
|
3 year
|
America
|
NR
|
69
|
95/90
|
Lumbar spine, UcOC, femoral neck, total body
|
44/43
|
− 9/− 8
|
− 1/5
|
− 18.5/0.8
|
|
Booth et al.(WK1)
|
2008
|
500 μg
|
600 mg
|
K1
|
3 year
|
America
|
NR
|
68
|
134/133
|
Lumbar spine, femoral neck, total body, UcOC
|
9/9
|
− 18/− 18
|
− 9/− 8
|
− 18.7/3.1
|
|
Cheung (K1)
|
2008
|
5 mg
|
1500 mg
|
K1
|
4 year
|
Canada
|
26.1
|
58.9
|
33/40
|
Lumbar spine, UcOC, femoral neck, hip
|
− 3.2/− 4.9
|
NR
|
− 14.2/− 19.2
|
− 21.2/− 2
|
|
Bolton (K1)
|
2007
|
30 μg
|
1000 mg
|
K1
|
2 year
|
Scottish
|
26.15
|
67.8
|
49/56
|
Femoral neck, radius
|
NR
|
NR
|
1/0.7
|
NR
|
|
Purwosunu (K2)
|
2006
|
45 mg
|
1500 mg
|
K2
|
1 year
|
Indonesia
|
23.8
|
60.9
|
33/30
|
Lumbar spine, UcOC
|
1.74/1.4
|
NR
|
NR
|
− 58.3/− 9.9
|
